Share Price and Basic Stock Data
Last Updated: December 11, 2025, 3:33 am
| PEG Ratio | 5.09 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Genomic Valley Biotech Ltd operates in the specialized fields of seeds, tissue culture, and biotechnology. The company’s financials reflect a challenging yet evolving revenue landscape. Over the last few years, sales have shown considerable volatility, peaking at ₹2.72 Cr in March 2023 before dwindling to ₹0.17 Cr by March 2024. Despite this sharp decline, recent quarters hint at a potential recovery, with sales rebounding slightly to ₹0.84 Cr in March 2025. This oscillation in revenue suggests operational instability, likely attributed to market conditions and possibly internal challenges. The company’s strategy in navigating these fluctuations will be critical for future growth, especially as it aims to establish a more consistent revenue stream in a competitive industry.
Profitability and Efficiency Metrics
In terms of profitability, Genomic Valley Biotech has experienced a rollercoaster ride. The operating profit margin (OPM) stood at a remarkable 93% in March 2023, showcasing an extraordinary efficiency in managing costs relative to sales during that period. However, OPM has since fluctuated, settling at 52.60% in March 2025, which still reflects a strong operational performance compared to many peers in the seed and biotech sectors. The return on equity (ROE) of 9.13% and return on capital employed (ROCE) of 11.32% indicate a solid ability to generate returns, albeit below the potential seen in more established firms. These metrics suggest that while the company has the ability to generate profits, the variability in sales and operating income could pose challenges to sustaining these efficiencies.
Balance Sheet Strength and Financial Ratios
Examining Genomic Valley’s balance sheet reveals a relatively strong financial position, particularly highlighted by the absence of borrowings, as reported at ₹0.00 Cr. This lack of debt provides the company with significant financial flexibility. The current ratio of 5.73 indicates that the company is well-positioned to cover its short-term liabilities, a reassuring sign for potential investors. However, the price-to-book value ratio of 4.59x suggests that the stock may be trading at a premium compared to its book value, which could raise eyebrows among value investors. Furthermore, the cash conversion cycle of 1,429.58 days is notably high, reflecting inefficiencies in converting inventory into cash. This metric could signal potential liquidity issues that investors need to monitor closely, as it may impact operational cash flow.
Shareholding Pattern and Investor Confidence
The shareholding structure of Genomic Valley Biotech demonstrates a significant shift in promoter holdings, which have decreased from 67.85% in December 2022 to 46.72% by June 2025. This reduction could indicate a dilution of control, potentially raising concerns about management’s commitment and long-term vision for the company. Conversely, the public shareholding has increased, reflecting growing interest among retail investors, which climbed to 53.29% by June 2025. The rising number of shareholders, which stood at 2,459, suggests that the company is attracting a broader base of retail investors. However, the lack of foreign institutional investors (FIIs) could imply a cautious stance from larger investors, possibly due to the company’s operational volatility and financial performance.
Outlook, Risks, and Final Insight
Looking ahead, Genomic Valley Biotech faces both opportunities and challenges. The recent uptick in sales and strong operating margins could bode well for future performance, but the company must address its high cash conversion cycle and maintain profitability in a volatile market. Risks include the ongoing fluctuations in revenue and the decreasing promoter shareholding, which may unsettle investor confidence. Additionally, the biotech sector is often subject to stringent regulations and market dynamics that could impact operations. For investors considering this stock, it is essential to weigh these risks against the potential for recovery and growth. A long-term perspective may be necessary, as the company navigates its path in a competitive landscape, balancing operational efficiency with market demands.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genomic Valley Biotech Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 6.67 Cr. | 21.8 | 99.8/21.0 | 66.7 | 12.8 | 0.00 % | 11.8 % | 9.68 % | 10.0 |
| Genesis IBRC India Ltd | 124 Cr. | 95.4 | 185/17.5 | 6.42 | 0.00 % | 51.6 % | 51.6 % | 10.0 | |
| Shreeoswal Seeds & Chemicals Ltd | 130 Cr. | 14.2 | 22.0/10.7 | 13.0 | 5.23 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 292 Cr. | 154 | 239/138 | 6.19 | 362 | 1.30 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 32.0 Cr. | 23.4 | 41.6/19.3 | 41.6 | 22.5 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 182.00 Cr | 61.76 | 31.87 | 81.79 | 0.26% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.03 | 0.02 | 0.67 | 1.00 | 0.06 | 0.07 | 0.04 | 0.00 | 0.16 | 0.21 | 0.22 | 0.26 | 0.09 |
| Expenses | 1.08 | 0.05 | 0.63 | 0.07 | 0.03 | 0.05 | 0.02 | 0.04 | 0.03 | 0.07 | 0.06 | 0.26 | 0.06 |
| Operating Profit | -0.05 | -0.03 | 0.04 | 0.93 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.14 | 0.16 | 0.00 | 0.03 |
| OPM % | -4.85% | -150.00% | 5.97% | 93.00% | 50.00% | 28.57% | 50.00% | 81.25% | 66.67% | 72.73% | 0.00% | 33.33% | |
| Other Income | 0.52 | 0.10 | -0.89 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.46 | 0.06 | -0.85 | 0.98 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.15 | 0.16 | 0.00 | 0.03 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | 0.46 | 0.06 | -0.85 | 0.98 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.15 | 0.16 | -0.08 | 0.02 |
| EPS in Rs | 1.51 | 0.20 | -2.78 | 3.21 | 0.10 | 0.07 | 0.07 | -0.13 | 0.43 | 0.49 | 0.52 | -0.26 | 0.07 |
Last Updated: August 19, 2025, 2:45 pm
Below is a detailed analysis of the quarterly data for Genomic Valley Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.09 Cr.. The value appears to be declining and may need further review. It has decreased from 0.26 Cr. (Mar 2025) to 0.09 Cr., marking a decrease of 0.17 Cr..
- For Expenses, as of Jun 2025, the value is 0.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.26 Cr. (Mar 2025) to 0.06 Cr., marking a decrease of 0.20 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.03 Cr..
- For OPM %, as of Jun 2025, the value is 33.33%. The value appears strong and on an upward trend. It has increased from 0.00% (Mar 2025) to 33.33%, marking an increase of 33.33%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.03 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.02 Cr.. The value appears strong and on an upward trend. It has increased from -0.08 Cr. (Mar 2025) to 0.02 Cr., marking an increase of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.07. The value appears strong and on an upward trend. It has increased from -0.26 (Mar 2025) to 0.07, marking an increase of 0.33.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 1:03 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.09 | 0.03 | 0.11 | 0.44 | 0.59 | 0.99 | 0.85 | 0.21 | 0.07 | 2.72 | 0.17 | 0.84 | 0.78 |
| Expenses | 0.08 | 0.07 | 0.54 | 0.48 | 0.49 | 0.57 | 0.30 | 0.34 | 0.45 | 1.84 | 0.15 | 0.40 | 0.45 |
| Operating Profit | 0.01 | -0.04 | -0.43 | -0.04 | 0.10 | 0.42 | 0.55 | -0.13 | -0.38 | 0.88 | 0.02 | 0.44 | 0.33 |
| OPM % | 11.11% | -133.33% | -390.91% | -9.09% | 16.95% | 42.42% | 64.71% | -61.90% | -542.86% | 32.35% | 11.76% | 52.38% | 42.31% |
| Other Income | 0.01 | 0.07 | 0.16 | 0.01 | 0.03 | 0.01 | 0.01 | 0.00 | 0.50 | -0.22 | 0.00 | 0.00 | 0.01 |
| Interest | 0.01 | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.05 | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | -0.01 | -0.34 | -0.07 | 0.05 | 0.24 | 0.20 | -0.50 | 0.00 | 0.65 | 0.02 | 0.44 | 0.34 |
| Tax % | 0.00% | 0.00% | -2.94% | 0.00% | 40.00% | 0.00% | -40.00% | 12.00% | 0.00% | 0.00% | 20.45% | ||
| Net Profit | 0.00 | -0.01 | -0.33 | -0.07 | 0.03 | 0.23 | 0.29 | -0.56 | -0.01 | 0.65 | 0.02 | 0.36 | 0.25 |
| EPS in Rs | 0.00 | -0.03 | -1.08 | -0.23 | 0.10 | 0.75 | 0.95 | -1.83 | -0.03 | 2.13 | 0.07 | 1.18 | 0.82 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -3200.00% | 78.79% | 142.86% | 666.67% | 26.09% | -293.10% | 98.21% | 6600.00% | -96.92% | 1700.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 3278.79% | 64.07% | 523.81% | -640.58% | -319.19% | 391.32% | 6501.79% | -6696.92% | 1796.92% |
Genomic Valley Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 40% |
| 5 Years: | 0% |
| 3 Years: | 129% |
| TTM: | 189% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 44% |
| 5 Years: | 4% |
| 3 Years: | 42% |
| TTM: | 92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | % |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 2% |
| 3 Years: | 12% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 10, 2025, 4:23 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves | 1.85 | 1.84 | 1.51 | 1.44 | 1.47 | 1.71 | 1.99 | 1.43 | -0.18 | 0.47 | 0.49 | 0.84 | 0.87 |
| Borrowings | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 1.48 | 1.48 | 1.55 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Other Liabilities | 0.61 | 0.80 | 0.73 | 0.78 | 1.41 | 0.94 | 1.49 | 1.59 | 0.92 | 0.90 | 0.79 | 0.47 | 0.41 |
| Total Liabilities | 6.26 | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.33 |
| Fixed Assets | 3.02 | 3.15 | 3.18 | 3.63 | 4.12 | 4.31 | 4.47 | 5.86 | 1.75 | -0.00 | -0.00 | 0.01 | 0.01 |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | 0.38 | 0.49 | 0.49 | 0.49 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | 0.55 | 0.11 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.02 | -0.00 | -0.00 |
| Other Assets | 3.24 | 2.74 | 2.75 | 2.39 | 2.18 | 2.38 | 3.05 | 1.27 | 2.04 | 4.42 | 4.31 | 4.35 | 4.32 |
| Total Assets | 6.26 | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.33 |
Below is a detailed analysis of the balance sheet data for Genomic Valley Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 3.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.05 Cr..
- For Reserves, as of Sep 2025, the value is 0.87 Cr.. The value appears strong and on an upward trend. It has increased from 0.84 Cr. (Mar 2025) to 0.87 Cr., marking an increase of 0.03 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.41 Cr.. The value appears to be improving (decreasing). It has decreased from 0.47 Cr. (Mar 2025) to 0.41 Cr., marking a decrease of 0.06 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4.33 Cr.. The value appears to be improving (decreasing). It has decreased from 4.36 Cr. (Mar 2025) to 4.33 Cr., marking a decrease of 0.03 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 4.32 Cr.. The value appears to be declining and may need further review. It has decreased from 4.35 Cr. (Mar 2025) to 4.32 Cr., marking a decrease of 0.03 Cr..
- For Total Assets, as of Sep 2025, the value is 4.33 Cr.. The value appears to be declining and may need further review. It has decreased from 4.36 Cr. (Mar 2025) to 4.33 Cr., marking a decrease of 0.03 Cr..
Notably, the Reserves (0.87 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.74 | -0.79 | -1.18 | -0.79 | -0.65 | -1.06 | -0.93 | -1.68 | -0.38 | 0.88 | 0.02 | 0.44 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 960.30 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 486.67 | ||||||
| Days Payable | 17.38 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 1,429.58 |
| Working Capital Days | 7,746.11 | -8,881.67 | -1,659.09 | -514.32 | -804.24 | 55.30 | -176.06 | -1,251.43 | 4,849.29 | 221.42 | 4,530.29 | 916.85 |
| ROCE % | 0.41% | 0.35% | -5.84% | -0.57% | 0.57% | 4.17% | 5.96% | -5.10% | -8.54% | 28.48% | 0.57% | 11.83% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 |
| Diluted EPS (Rs.) | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 |
| Cash EPS (Rs.) | 1.17 | 0.05 | 2.15 | 0.24 | -1.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 12.76 | 11.60 | 11.55 | 9.42 | 14.69 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 12.76 | 11.60 | 11.55 | 9.42 | 14.69 |
| Revenue From Operations / Share (Rs.) | 2.76 | 0.54 | 8.91 | 0.23 | 0.68 |
| PBDIT / Share (Rs.) | 1.45 | 0.05 | 3.02 | -0.96 | -0.44 |
| PBIT / Share (Rs.) | 1.45 | 0.04 | 2.99 | -1.24 | -1.06 |
| PBT / Share (Rs.) | 1.45 | 0.04 | 2.12 | -1.38 | -1.64 |
| Net Profit / Share (Rs.) | 1.17 | 0.04 | 2.12 | -0.03 | -1.83 |
| PBDIT Margin (%) | 52.60 | 9.83 | 33.83 | -416.43 | -64.94 |
| PBIT Margin (%) | 52.30 | 9.17 | 33.54 | -535.97 | -155.88 |
| PBT Margin (%) | 52.30 | 9.17 | 23.83 | -596.37 | -241.16 |
| Net Profit Margin (%) | 42.19 | 9.19 | 23.81 | -13.23 | -268.67 |
| Return on Networth / Equity (%) | 9.13 | 0.42 | 18.38 | -0.32 | -12.45 |
| Return on Capital Employeed (%) | 11.32 | 0.42 | 25.89 | -10.55 | -4.80 |
| Return On Assets (%) | 8.17 | 0.35 | 14.66 | -0.24 | -7.33 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 |
| Total Debt / Equity (X) | 0.00 | 0.16 | 0.17 | 0.00 | 0.34 |
| Asset Turnover Ratio (%) | 0.19 | 0.03 | 0.66 | 0.01 | 0.02 |
| Current Ratio (X) | 5.73 | 3.68 | 2.88 | 5.31 | 0.18 |
| Quick Ratio (X) | 5.10 | 3.68 | 2.88 | 5.31 | 0.18 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 0.00 | -6.89 | -0.76 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 0.00 | -9.05 | -2.15 |
| Enterprise Value (Cr.) | 17.85 | 11.20 | 7.21 | 7.56 | 8.74 |
| EV / Net Operating Revenue (X) | 21.15 | 67.84 | 2.65 | 107.10 | 42.02 |
| EV / EBITDA (X) | 40.21 | 689.51 | 7.83 | -25.72 | -64.70 |
| MarketCap / Net Operating Revenue (X) | 21.21 | 64.23 | 2.44 | 107.14 | 34.64 |
| Price / BV (X) | 4.59 | 2.99 | 1.88 | 2.63 | 1.61 |
| Price / Net Operating Revenue (X) | 21.21 | 64.28 | 2.44 | 107.14 | 34.65 |
| EarningsYield | 0.01 | 0.00 | 0.09 | 0.00 | -0.07 |
After reviewing the key financial ratios for Genomic Valley Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 1.17, marking an increase of 1.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 1.17, marking an increase of 1.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 3. It has increased from 0.05 (Mar 24) to 1.17, marking an increase of 1.12.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 12.76. It has increased from 11.60 (Mar 24) to 12.76, marking an increase of 1.16.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 12.76. It has increased from 11.60 (Mar 24) to 12.76, marking an increase of 1.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2.76. It has increased from 0.54 (Mar 24) to 2.76, marking an increase of 2.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 2. It has increased from 0.05 (Mar 24) to 1.45, marking an increase of 1.40.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 1.45, marking an increase of 1.41.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 1.45, marking an increase of 1.41.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 2. It has increased from 0.04 (Mar 24) to 1.17, marking an increase of 1.13.
- For PBDIT Margin (%), as of Mar 25, the value is 52.60. This value is within the healthy range. It has increased from 9.83 (Mar 24) to 52.60, marking an increase of 42.77.
- For PBIT Margin (%), as of Mar 25, the value is 52.30. This value exceeds the healthy maximum of 20. It has increased from 9.17 (Mar 24) to 52.30, marking an increase of 43.13.
- For PBT Margin (%), as of Mar 25, the value is 52.30. This value is within the healthy range. It has increased from 9.17 (Mar 24) to 52.30, marking an increase of 43.13.
- For Net Profit Margin (%), as of Mar 25, the value is 42.19. This value exceeds the healthy maximum of 10. It has increased from 9.19 (Mar 24) to 42.19, marking an increase of 33.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.13. This value is below the healthy minimum of 15. It has increased from 0.42 (Mar 24) to 9.13, marking an increase of 8.71.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.32. This value is within the healthy range. It has increased from 0.42 (Mar 24) to 11.32, marking an increase of 10.90.
- For Return On Assets (%), as of Mar 25, the value is 8.17. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 8.17, marking an increase of 7.82.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.19. It has increased from 0.03 (Mar 24) to 0.19, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 5.73. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 5.73, marking an increase of 2.05.
- For Quick Ratio (X), as of Mar 25, the value is 5.10. This value exceeds the healthy maximum of 2. It has increased from 3.68 (Mar 24) to 5.10, marking an increase of 1.42.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 17.85. It has increased from 11.20 (Mar 24) to 17.85, marking an increase of 6.65.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 21.15. This value exceeds the healthy maximum of 3. It has decreased from 67.84 (Mar 24) to 21.15, marking a decrease of 46.69.
- For EV / EBITDA (X), as of Mar 25, the value is 40.21. This value exceeds the healthy maximum of 15. It has decreased from 689.51 (Mar 24) to 40.21, marking a decrease of 649.30.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 21.21. This value exceeds the healthy maximum of 3. It has decreased from 64.23 (Mar 24) to 21.21, marking a decrease of 43.02.
- For Price / BV (X), as of Mar 25, the value is 4.59. This value exceeds the healthy maximum of 3. It has increased from 2.99 (Mar 24) to 4.59, marking an increase of 1.60.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 21.21. This value exceeds the healthy maximum of 3. It has decreased from 64.28 (Mar 24) to 21.21, marking a decrease of 43.07.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genomic Valley Biotech Ltd:
- Net Profit Margin: 42.19%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.32% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.13% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.1
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 66.7 (Industry average Stock P/E: 31.87)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 42.19%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Seeds/Tissue Culture/Bio Technology | 4KM Stone, Berry Charra Road, P.O. Tanda Hari, Jhajjar District Haryana 124507 | genomicvalley@gmail.com http://www.genomicvalley.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Yogesh Agrawal | Managing Director |
| Mrs. Parul Agrawal | Non Executive Director |
| Mr. Ashok Kumar | Non Executive Director |
| Mr. Satendra Kumar Goyal | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd's intrinsic value (as of 11 December 2025) is 67.44 which is 209.36% higher the current market price of 21.80, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 6.67 Cr. market cap, FY2025-2026 high/low of 99.8/21.0, reserves of ₹0.87 Cr, and liabilities of 4.33 Cr.
What is the Market Cap of Genomic Valley Biotech Ltd?
The Market Cap of Genomic Valley Biotech Ltd is 6.67 Cr..
What is the current Stock Price of Genomic Valley Biotech Ltd as on 11 December 2025?
The current stock price of Genomic Valley Biotech Ltd as on 11 December 2025 is 21.8.
What is the High / Low of Genomic Valley Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genomic Valley Biotech Ltd stocks is 99.8/21.0.
What is the Stock P/E of Genomic Valley Biotech Ltd?
The Stock P/E of Genomic Valley Biotech Ltd is 66.7.
What is the Book Value of Genomic Valley Biotech Ltd?
The Book Value of Genomic Valley Biotech Ltd is 12.8.
What is the Dividend Yield of Genomic Valley Biotech Ltd?
The Dividend Yield of Genomic Valley Biotech Ltd is 0.00 %.
What is the ROCE of Genomic Valley Biotech Ltd?
The ROCE of Genomic Valley Biotech Ltd is 11.8 %.
What is the ROE of Genomic Valley Biotech Ltd?
The ROE of Genomic Valley Biotech Ltd is 9.68 %.
What is the Face Value of Genomic Valley Biotech Ltd?
The Face Value of Genomic Valley Biotech Ltd is 10.0.